Smith Melody, García-Martínez Elena, Pitter Michael R, Fucikova Jitka, Spisek Radek, Zitvogel Laurence, Kroemer Guido, Galluzzi Lorenzo
Department of Medicine and Immunology Program, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Hematology and Oncology Department, Hospital Universitario Morales Meseguer, Murcia, Spain.
Oncoimmunology. 2018 Oct 11;7(12):e1526250. doi: 10.1080/2162402X.2018.1526250. eCollection 2018.
Toll-like receptor (TLR) agonists demonstrate therapeutic promise as immunological adjuvants for anticancer immunotherapy. To date, three TLR agonists have been approved by US regulatory agencies for use in cancer patients. Additionally, the potential of hitherto experimental TLR ligands to mediate clinically useful immunostimulatory effects has been extensively investigated over the past few years. Here, we summarize recent preclinical and clinical advances in the development of TLR agonists for cancer therapy.
Toll样受体（TLR）激动剂作为抗癌免疫疗法的免疫佐剂显示出治疗前景。迄今为止，三种TLR激动剂已获美国监管机构批准用于癌症患者。此外，在过去几年中，人们广泛研究了迄今仍处于实验阶段的TLR配体介导临床上有用的免疫刺激作用的潜力。在此，我们总结了TLR激动剂用于癌症治疗的最新临床前和临床进展。
